Biotech Values

[DewDiligence]

>Given that there is some indication of Provenge efficacy, it seems to me it would be hard to do a trial now without crossovers allowed. So, ironically, the more effective that Provenge seems to be, the harder it becomes in practice to do a rigorous trial.<

All drug sponsors face this issue to some degree.

It astonishes me that some of the DNDN bulls who post on message boards think that DNDN is entitled to special treatment from the FDA on matters that other sponsors deal with routinely.